Inventiva Reveals Preliminary 2025 Half-Year Financials
Inventiva Reveals Preliminary 2025 Half-Year Financials 🕓 Estimated Reading Time: 5 minutes Inventiva S.A. released its preliminary financial information for the first half of 2025, highlighting key performance indicators. The report details the company's cash position, revenue generation, and significant investment in research and development. Despite an expected net loss, the biopharmaceutical firm maintains a robust financial runway to support its clinical pipeline. Analysts are reviewing the figures for insights into the progress of Inventiva's lead programs, notably those addressing NASH and auto-immune diseases. Overview Inventiva S.A. (Euronext Paris: IVA), a clinical-stage biopharmaceutical company, today announced its preliminary financial information for the first six months of 2025. The Inventiva financial report , released on July 29, 2025, via GlobeNewswire, provides a snapshot of the company's financial health and operational expenditures during a period mark...